Effect of growth hormone and oxandrolone singly and together on growth rate in girls with X chromosome abnormalities

Rudman, Daniel; Goldsmith, Martin A.; Kutner, Michael; Blackston, Dwain

doi:10.1016/s0022-3476(80)80349-0

Cited by 61 publications

(14 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Short stature has been treated with anabolic steroids, low doses of oestrogen, human growth hormone (hGH), or a combination therapy (1)(2)(3)(4)(5). Since the successful synthesis of hGH by recombinant DNA technology (6), several investigators have reported the safety and biological activity of recombinant hGH (rhGH) in humans.…”

Section: Introductionmentioning

confidence: 99%

Clinical trials of GH treatment in patients with Turner's syndrome in Japan--a consideration of final height. The Committee for the Treatment of Turner's Syndrome

Takano

Ogawa

Tanaka

et al. 1997

European Journal of Endocrinology

View full text Add to dashboard Cite

Clinical trials of human GH (hGH) therapy in Turner's syndrome were started in 1986. Between 1986 and 1990, 362 patients were enrolled; 115 were treated for more than 6 years. The age at the start of treatment ranged from 5 to 18 years (mean 10 years). Fifty-one patients received hGH at a weekly dosage of 0.5 IU/kg and 64 received 1.0 IU/kg by daily s.c. injection. Both treatment groups showed a statistically significant growth increase during the initial 4 years of treatment. The rate of increase in height was significantly greater for the initial 2 years with the high dose than with the low dose. The increases in height over 6 years of treatment (expressed by S.D. score for chronological age) were 1.48 Ϯ 0.8 with 0.5 IU/kg per week and 1.80 Ϯ 1.0 with 1.0 IU/kg per week. To date, 260 patients have stopped GH therapy. In 32% of them, the height attained was above the ¹2 S.D. value for normal girls. In 27%, the growth rate was not sufficient when they stopped treatment. The mean final height (growth rate Յ1.0 cm/year) of patients treated for more than 6 years was 142.2 Ϯ 6.5 cm (n ¼ 15) with 0.5 IU/kg per week, and 144.3 Ϯ 3.9 cm (n ¼ 15) with 1.0 IU/kg per week. The adult height was improved by GH treatment, although final height did not differ statistically between the two dose regimens. No remarkable adverse events occurred during the treatment. These results indicate that hGH treatment improves the final height in patients with Turner's syndrome.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical trials of GH treatment in patients with Turner's syndrome in Japan--a consideration of final height. The Committee for the Treatment of Turner's Syndrome

Takano

Ogawa

Tanaka

et al. 1997

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…To treat short stature, anabolic steroids and low doses of estrogen, and/or hGH have been used (Tanner et al, 1971;Urban et al, 1979;Rudman et al, 1980;Ross et al, 1983;Stahnke 1984).…”

mentioning

confidence: 99%

Treatment of 94 Patients with Turner's Syndrome with Recombinant Human Growth Hormone (SM-9500) for Two Years. The Results of a Multicentric Study in Japan.

Takano

Shizume²,

Hibi³

1989

Endocrinol Japon

View full text Add to dashboard Cite

show abstract

“…Oxandrolone, a non-aramatizable anabolic agent with mild androgenic properties, had for a long time been used in patients with short stature of various etiologies and was combined with GH in many studies due to the supra-additive action of this combination therapy on growth and IGF-I concentrations [5, 6]. …”

Section: Introductionmentioning

confidence: 99%

Growth Hormone Therapy in Patients with Turner Syndrome

Haeusler¹

1998

Horm Res Paediatr

View full text Add to dashboard Cite

This article summarizes the published data on final height after growth-promoting therapy in Turner syndrome. Using growth hormone (GH) doses ranging between 0.5 and 1.2 IU/kg/week, final height after therapy is improved by 1.5–9.3 cm [final height after therapy vs. projected adult height (PAH)] within various studies. There is no obvious GH dose-response relationship, but a better estimated benefit from therapy seems to result in those studies that combined even rather low GH doses with the anabolic steroid oxandrolone. It is not possible to retrospectively define an optimal treatment regime out of the various published data due to different GH doses, age and dosage of estrogen replacement therapy and the variable methods for calculating the benefit from therapy. It seems to be essential to start estrogens at a safe bone age (> 13 years) in very low doses. Higher GH doses (up to 2.0 IU/kg/week) led to a better growth response during the first years of therapy but data on final height are still to be awaited.

show abstract

Effect of growth hormone and oxandrolone singly and together on growth rate in girls with X chromosome abnormalities

Cited by 61 publications

References 16 publications

Clinical trials of GH treatment in patients with Turner's syndrome in Japan--a consideration of final height. The Committee for the Treatment of Turner's Syndrome

Clinical trials of GH treatment in patients with Turner's syndrome in Japan--a consideration of final height. The Committee for the Treatment of Turner's Syndrome

Treatment of 94 Patients with Turner's Syndrome with Recombinant Human Growth Hormone (SM-9500) for Two Years. The Results of a Multicentric Study in Japan.

Growth Hormone Therapy in Patients with Turner Syndrome

Contact Info

Product

Resources

About